Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
http://img.marketwire.com/rss/mwPBTR.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announces  apr  april  cannabis  company  development  marketwired apr  marketwired april  marketwired  new  research  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials



Marketwired - Trials



Last Build Date: Fri, 21 Apr 2017 19:39:22 EDT

Copyright: Copyright: (C) Marketwired
 



Global Quest Launches Carepoint Nutrients, LLC for Distribution of Natural Based Relief and Sleep Disorder Formulas

Fri, 21 Apr 2017 19:02:49 EDT

ENGLEWOOD, CO--(Marketwired - Apr 21, 2017) - Global Quest, Ltd. (OTC PINK: GLBB) is pleased to announce the launch of Carepoint Nutrients, LLC, a wholly owned subsidiary with the corporate mission of distributing multiple proprietary lines of nutrient supplements. Carepoint Nutrients is set up to serve medical practices, dispensaries and consumers directly. The company's unique product lines include several formulas designed to provide effective relief for patients who suffer from inflammation and sleep disorders. These nutrient supplement products are distributed under the Carepoint brand name and patients may purchase them directly from doctors, dispensaries or via the company website. Patients can also choose to sign a subscription agreement for convenient monthly deliveries direct to their homes.




Med Ad News Recognizes Healthcare Communications Excellence At 2017 Manny Awards

Fri, 21 Apr 2017 15:27:14 EDT

LIVINGSTON, NJ--(Marketwired - April 21, 2017) - Med Ad News -- the leading pharmaceutical business and marketing publication -- announces the winners for the 2017 Manny Awards, celebrating the best in the healthcare communications industry. The black-tie gala affair occurred last night at Pier Sixty in New York City with 500-plus people in attendance. Twenty awards were bestowed throughout the night to healthcare agencies achieving excellence in various categories.




Cannabis Science Continues Expansions as it Negotiates to Acquire Two Medical Marijuana Dispensaries in Los Angeles, California; The Company Expects to Sign Closing Documents Shortly

Fri, 21 Apr 2017 12:12:22 EDT

CBIS Negotiates for Two Los Angeles, California Medical Marijuana Dispensaries Right Before the Global Health Catalyst Summit at Harvard




Clinical Ink Extends eCOA and Risk-Based Monitoring Capabilities

Fri, 21 Apr 2017 12:00:00 EDT

Latest SureSource(R) Release Expands eSource Functionality and Platform Interoperability




Mount Tam Biotechnologies Announces that the European Patent Office Has Allowed a Key Patent for Lead Compound TAM-01

Fri, 21 Apr 2017 06:00:00 EDT

NOVATO, CA--(Marketwired - Apr 21, 2017) - Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors, is pleased to announce that the European Patent Office has allowed a key patent for TAM-01, a novel mTOR modulator, targeting unmet need in systemic lupus erythematosus (SLE). The patent, owned by the Buck Institute for Research on Aging and licensed exclusively to Mount Tam Biotechnologies, provides composition of matter protection for Mount Tam's lead compound in Europe, further strengthening Mount Tam's strong intellectual property position in the United States and Japan.




Vernalis PLC: FDA Issues a Complete Response Letter on CCP-07 NDA

Fri, 21 Apr 2017 02:00:00 EDT

WINNERSH, UNITED KINGDOM--(Marketwired - Apr 21, 2017) - Vernalis PLC (LSE: VER)




Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD

Thu, 20 Apr 2017 16:30:00 EDT

PHILADELPHIA, PA--(Marketwired - Apr 20, 2017) -




Former Megaupload Programming Team Joins mCig, Inc. in the Cannabis Tech Space

Thu, 20 Apr 2017 12:17:53 EDT

HENDERSON, NV--(Marketwired - Apr 20, 2017) - mCig, Inc., (OTCQB: MCIG) a leading distributor of innovative products, technologies and services for the global medical marijuana industry, is pleased to announce the achievement of acquiring part of the former Megaupload development team. The team is led by Chief Technologist, Andrus Nomm, recognized as the senior operative and programming lead in the popular online file sharing, streaming and ad serving websites of MEGAupload, MEGAclick and MEGAvideo. The sites served approximately 50 million users per day over 6500+ servers, monetizing over a quarter billion USD in advertising and subscription revenue. 




Ogilvy CommonHealth Worldwide strengthens its creative offering with executive-level new hire and promotions

Thu, 20 Apr 2017 11:26:36 EDT

PARSIPPANY, NJ--(Marketwired - Apr 20, 2017) - Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com) and a WPP Health & Wellness company (NASDAQ: WPPGY) (www.wpp.com), today announced one new hire and three promotions at the executive vice president, creative director level in the network's New Jersey headquarters.




Cannabis Science Issues First Quarter Update and Celebrates 4/20 With Unprecedented Revenue Growth Projections and Sustainable Equity Value Looking Forward to More Quarterly Growth and Progress Reports

Thu, 20 Apr 2017 11:18:02 EDT

IRVINE, CA--(Marketwired - Apr 20, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, recently announced a pending offering memorandum for expansion capital, another large drug development deal, and an expedited seeding schedule, all of which are expected to create sustainable equity value and unprecedented revenue growth for the company.




Propanc CEO James Nathanielsz's FDA Policy Proposals Published in Pharma Trade Media

Thu, 20 Apr 2017 10:07:05 EDT

Company completes 1-for-250 reverse split and name change to Propanc Biopharma Inc.




AlumiFuel Announces Plans for Cannabis Grow Facility

Thu, 20 Apr 2017 09:00:00 EDT

CENTENNIAL, CO--(Marketwired - Apr 20, 2017) - AlumiFuel Power Corporation (OTC PINK: AFPW) ("AlumiFuel" or the "Company") today announced that it has entered into negotiations, via an unaffiliated third party, for the launch and operation of a cannabis grow facility.




MyDx Releases Earnings Call Investor Presentation

Thu, 20 Apr 2017 09:00:00 EDT

Invites Industry and Media to Learn More About MyDx Breakthrough Technology Setting the Foundation for the Future of Cannabis




Atossa Genetics Receives Positive Interim Review From Independent Safety Committee in Phase 1 Endoxifen Dose Escalation Study

Thu, 20 Apr 2017 08:15:00 EDT

SEATTLE, WA--(Marketwired - Apr 20, 2017) -  Atossa Genetics, Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company, today announced that it has received a positive interim review on its Phase 1 study of endoxifen, which is an active metabolite of the FDA approved drug tamoxifen, which is indicated for breast cancer and breast cancer prevention in high risk patients. The Independent Safety Committee reviewed the blinded data generated from the first cohort of the study (8 subjects) and concluded that the study may advance to the next dosing level.




Vitality Biopharma Releases Clinical Report of Cannabinoid Therapy for Pediatric IBD

Thu, 20 Apr 2017 08:00:00 EDT

Cannabinoid therapy was able to successfully induce and maintain long-term remission in case study of drug-resistant pediatric inflammatory bowel disease




Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome

Thu, 20 Apr 2017 08:00:00 EDT

LEXINGTON, MA--(Marketwired - Apr 20, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotech company devoted to treating diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules, today announced that the United States Food and Drug Administration (FDA) has granted Aldeyra's novel compound ADX-102 orphan drug designation for the treatment of congenital ichthyosis, a severe skin disease characteristic of Sjögren-Larsson Syndrome (SLS). There are no FDA-approved therapies specifically indicated for the treatment of SLS, and ADX-102 is believed to be the only potential SLS therapy in clinical development.




The New Gold Standards of IRT Delivery for Clinical Trials, New Webinar Hosted by Xtalks

Thu, 20 Apr 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - April 20, 2017) - In a live presentation, Grant Dietrich, industry expert and Vice President of Strategic Partnerships at YPrime will discuss how emerging IRT system functionality goes beyond management of patient randomization and drug supply.




SPYRUS(R) Announces Hardware "Root of Trust" Product Family Supporting Microsoft Azure IoT Hub

Thu, 20 Apr 2017 03:01:00 EDT

SPYRUS FIPS 140-2 Level 3 Certified Devices Bring Strong Authentication to SAS Token and TLS/SSL Schema Azure IoT Hub




Cosmos Holdings, Inc. Announces Full-Year 2016 Results

Wed, 19 Apr 2017 17:58:23 EDT

Revenue Improved 1,166 Percent and Gross Profit Improved 1,126 Percent Year over Year




Cannabis Science Senior Executives Set to Present Drug Development Initiatives to Key Stakeholders Around the World at the Upcoming Global Health Catalyst Summit at Harvard Medical School Next Week, April 28 - 30th 2017

Wed, 19 Apr 2017 13:03:01 EDT

Cannabis Science Versus Cancer and Other Malignancies and the Palliative Care and Mental Health Sessions will be live-streamed to an audience worldwide




Parvus Therapeutics Announces Exclusive Worldwide License and Collaboration Agreement for the Development and Commercialization of Its Lead Nanomedicine to Treat Type 1 Diabetes

Wed, 19 Apr 2017 12:00:00 EDT

CALGARY, AB--(Marketwired - April 19, 2017) - Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune suppression, has entered into a license and collaboration agreement with Novartis for its lead Navacim for treating type 1 diabetes. Navacims constitute a novel pharmacological class of therapeutic comprised of nanoparticles (NPs) coated with disease-relevant peptide-major histocompatibility complexes (pMHCs) that alter the behavior of disease-causing T lymphocytes. Navacims are the first biopharmaceuticals to demonstrate in preclinical models the ability to restore immune tolerance in a disease-specific manner through in vivo formation and expansion of regulatory T-cells (T-regs) without causing general immune suppression.




Plandai Biotechnology Sets Aggressive Agenda for 2017

Wed, 19 Apr 2017 09:00:00 EDT

NEW YORK, NY--(Marketwired - April 19, 2017) - Plandaí Biotechnology (OTCQB: PLPL) recently presented investors with its outlook for 2017 and a number of milestones that the company plans to accomplish in 2017. Plandaí's plans are certainly aggressive and representative of the new Chief Operating Officer (COO) -- someone we feel is ideally suited to move the company forward. It didn't take long at all for the new COO, Callum Cottrell-Duffield, to put his stamp on the company's future.




Desert Oasis Healthcare Establishes Center for Research and Healthcare Innovation Featuring Altura's HCP Studies(TM) Mobile Platform

Wed, 19 Apr 2017 08:30:00 EDT

Altura's Novel Study Engagement Platform(TM) to Help Create Optimized Clinical Study Ecosystem for Patients and Healthcare Providers




NetworkNewsWire Announces Publication Highlighting Advances in Cancer Therapy

Wed, 19 Apr 2017 08:30:00 EDT

NEW YORK, NY--(Marketwired - Apr 19, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring TapImmune, Inc. (NASDAQ: TPIV), an NNW client focused on leading the field of oncology with its next-generation T-cell vaccines and novel immunotherapy platforms.




Lion Biotechnologies Announces Strategic Alliance with MD Anderson Cancer Center to Conduct Clinical Trials of TILs in Multiple Solid Tumors

Wed, 19 Apr 2017 08:00:00 EDT

SAN CARLOS, CA and HOUSTON, TX--(Marketwired - April 19, 2017) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology and The University of Texas MD Anderson Cancer Center, today announced a multi-year strategic alliance agreement involving multi-arm clinical trials to evaluate the safety and efficacy of TIL therapy in ovarian cancer, various sarcomas, and pancreatic cancer. In addition, preclinical research will explore the expansion of TIL in other rare tumor types.




Technology Solutions for Late Phase Research: Optimizing Real World Data Assets, New Webinar Hosted by Xtalks

Wed, 19 Apr 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - April 19, 2017) - Michael Cook, Principal of Epidemiology and Bill Row, Divisional Principal of Real World Evidence both from ICON Commercialisation and Outcomes will outline how technological innovation can be applied to late phase research studies and how the smart application of that technology can enhance use of real world data (RWD) assets. The live event will take place on Monday, May 1, 2017 at 11am EDT (4pm BST/UK).




Amedica Announces Delayed Filing of Annual Report on Form 10-K and Receipt of Nasdaq Letter

Wed, 19 Apr 2017 07:00:00 EDT

SALT LAKE CITY, UT--(Marketwired - Apr 19, 2017) - Amedica Corporation (NASDAQ: AMDA), an innovative biomaterial company which develops and manufactures silicon nitride as a platform for biomedical applications, announced today that it is delaying the filing of its Annual Report on Form 10-K for the year ended December 31, 2016 ("Form 10-K").




Non-Profit MAPS to Utilize Full Range of Medrio Functionality for Pivotal PTSD Study

Tue, 18 Apr 2017 12:00:00 EDT

SAN FRANCISCO, CA--(Marketwired - April 18, 2017) - The Multidisciplinary Association for Psychedelic Studies (MAPS), a California-based non-profit research organization, has selected Medrio, a Software as a Service (SaaS) company offering electronic data capture services to clinical trials, as its data management system for a Phase 3 clinical trial testing the efficacy and safety of MDMA-assisted psychotherapy as a treatment for post-traumatic stress disorder (PTSD). MAPS has utilized Medrio for its research in the past, but the new agreement represents its first purchase of the full range of modules in Medrio's software, including eSource, randomization, dictionary coding, and others. The agreement will commence in 2018 and remain in place until 2020. In preparation for the Phase 3 studies, MAPS is currently hosting their Phase 3 Investigator Meeting in Oakland, CA.




Bradmer Announces Fourth Quarter and Full Year 2016 Financial Results

Tue, 18 Apr 2017 11:46:08 EDT

TORONTO, ONTARIO--(Marketwired - April 18, 2017) - Bradmer Pharmaceuticals Inc. (NEX:BMR.H) ("Bradmer" or the "Company") today announced its fourth quarter and full year 2016 financial results.




Advantis Corp. Set To File for California Commercial Distribution License

Tue, 18 Apr 2017 09:28:00 EDT

NEWPORT BEACH, CA--(Marketwired - Apr 18, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) filed paperwork in California last week as a first step toward applying for commercial recreational marijuana distribution license. Advantis CEO, Christopher Swartz, says the company is preparing to be "first in line" once the state sets the recreational licensing process in motion.




MyDx Announces Fiscal Year 2016 Results

Tue, 18 Apr 2017 09:20:00 EDT

SAN DIEGO, CA--(Marketwired - Apr 18, 2017) -  MyDx, Inc. (OTCQB: MYDX), a rapidly growing science and technology company that has developed MyDx®, the first multi-use handheld chemical analyzer for consumers, announces its 2016 fiscal year earnings results and management analysis. 




Proto Script Pharmaceutical Signs Medical Equipment Supply Agreement with PAKmed

Tue, 18 Apr 2017 09:03:05 EDT

RANCHO CUCAMONGA, CA--(Marketwired - Apr 18, 2017) - Proto Script Pharmaceutical Corp. dba PSP Homecare ("PSP" or the "Company") (OTC PINK: PSCR), a durable medical equipment provider, is pleased to announce that the Company has entered into a Supply Agreement with PAKmed LLC ("PAKmed"), a manufacturer of premium orthotic braces based in Louisville, Kentucky.




eWellness Plans the Launching of Multiple New Patient, Physician & PT Centric Platforms and Mobile Apps

Tue, 18 Apr 2017 09:00:00 EDT

CULVER CITY, CA--(Marketwired - Apr 18, 2017) - eWellness Healthcare Corporation - (OTCQB: EWLL), a provider of the state of the art PHZIO Platform for the physical therapy and telehealth markets, announced today that it plans to launch multiple new patient, physician and physical therapy (PT) centric platforms and mobile Apps over the next 8-10 weeks.




American Cannabis Company, Inc. Announces a New Client and License Applicant in Louisiana

Tue, 18 Apr 2017 08:30:00 EDT

DENVER, CO--(Marketwired - Apr 18, 2017) - American Cannabis Company, Inc. (OTCQB: AMMJ) (the "Company"), a business-to-business consulting firm and distributor of ancillary products and services to the cannabis industry, today announced it has secured its first retainer client (the "Client") in the state of Louisiana. The Client, CB Medical, LLC ("CB Medical"), is a newly formed entity that is one of the applicants for the LSU-sponsored medical marijuana program. LSU has indicated that it will select finalists for live presentations next month, and then it will determine a winner in June 2017.




Reading Health System Continues to Align and Engage Its Physician Leaders by Expanding the Reach of the Applied Physician Leadership Academy(C)

Tue, 18 Apr 2017 08:30:00 EDT

NEW YORK, NY--(Marketwired - Apr 18, 2017) - Reading Health System, in conjunction with The Leadership Development Group, is changing its culture by focusing on physician leadership, alignment, and engagement. This month twenty-eight of the top ranked physician leaders from Reading Health System (RHS) graduated from The Leadership Development Group's Applied Physician Leadership Academy (APLA©), an 18-month customized leadership development program, designed to engage and develop physician leaders. And in January 2017, twenty-six emerging physician leaders joined together from across the organization to kick off a second cohort of the APLA that will run through March 2018. The program, intended to engage, inspire, and motivate leadership development for physicians, includes structured training courses focusing on development of leadership skills and competencies; mentoring and networking, assessments, coaching and feedback; and the process to apply learning and develop leadership competencies through work on real business problems.




Pharmaceutical Industry Executive Brian W. Andersen Named Chief Business Officer at Asana Medical, Inc.

Tue, 18 Apr 2017 08:00:00 EDT

MIAMI LAKES, FL--(Marketwired - Apr 18, 2017) - Asana Medical, Inc., ("Asana," the "Company"), a regenerative medicine company that is developing a novel treatment for Inflammatory Bowel Disease ("IBD"), including Ulcerative Colitis and Crohn's Disease, is pleased to announce that Brian W. Andersen, an experienced industry executive with a proven record of commercial excellence, has been appointed as its Chief Business Officer.




Garlock to Exhibit at "Korea Pharm 2017"

Tue, 18 Apr 2017 08:00:00 EDT

PALMYRA, NY--(Marketwired - Apr 18, 2017) -




Lion Biotechnologies Highlights Publication of New Translational Data in Science for TIL Therapy for Treatment of Cervical Cancer

Tue, 18 Apr 2017 08:00:00 EDT

SAN CARLOS, CA--(Marketwired - April 18, 2017) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, highlighted today that a publication in the journal Science provided new translational data from a clinical trial of TIL therapy for the treatment of advanced metastatic cervical cancer conducted at the Surgery Branch of the National Cancer Institute (NCI). This trial has been supported in part by Lion under a Cooperative Research and Development Agreement (CRADA) with Dr. Steven Rosenberg, Chief of the Surgery Branch, National Cancer Institute (NCI), National Institutes of Health.




Si-Ware Systems Announces NeoSpectra Micro Development Kits

Tue, 18 Apr 2017 08:00:00 EDT

Development with NeoSpectra Micro Ushers in the Era of Universal Material Analysis




Aldeyra Therapeutics, Inc. Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial

Tue, 18 Apr 2017 08:00:00 EDT

LEXINGTON, MA--(Marketwired - Apr 18, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes, today announced that the last patient has completed dosing in Aldeyra's multi-center, double-blind, randomized Phase 2b clinical trial of ADX-102 in allergic conjunctivitis. 




Stealth Mark Expands ActiveDuty's Power for Covert Ops

Tue, 18 Apr 2017 08:00:00 EDT

HOFFMAN ESTATES, IL--(Marketwired - Apr 18, 2017) - Wellness Center USA, Inc. (OTCQB: WCUI), today announced that its wholly-owned subsidiary, StealthCo, Inc., dba Stealth Mark, is expanding its anti-counterfeiting ActiveDuty System to provide actionable intelligence in the worlds of money laundering and human trafficking/slavery. The scope of the work is being conducted in collaboration with prominent organizations, and is classified in nature.




Pharmaceutical Serialization for Late Starters -- With Live Industry Research Results from SEA Vision, New Webinar Hosted by Xtalks

Tue, 18 Apr 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - April 18, 2017) - In this live session, entitled 'pharmaceutical serialization for late starters', Carlos Machado, serialization director at SEA Vision US and Paolo Landriani, product manager at SEA Vision Italy will offer insight on how companies within the pharmaceutical industry can prepare for upcoming serialization regulations, with a view to guaranteeing long term success and compliance.




60-Second Liver assessment: SuperSonic Imagine will demonstrate the performance of Real-Time ShearWave(TM) Elastography at the upcoming International Liver Congress (ILC 2017) in Amsterdam

Tue, 18 Apr 2017 06:00:00 EDT

AIX-EN-PROVENCE, FRANCE--(Marketwired - Apr 18, 2017) - SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), a company specializing in ultrasound medical imaging, announced today that it will showcase the clinical benefits of its real-time ShearWaveT Elastography (SWET) technology for non-invasive assessment of patients with chronic liver disease at the International Liver Congress (ILC 2017) or EASL, April 19 - 23 in Amsterdam.




Reprints Desk s'associe à des distributeurs européens pour fournir un accès rapide au contenu bibliographique et aux données destinées aux chercheurs

Tue, 18 Apr 2017 03:00:00 EDT

Les accords de distribution de la filiale de Research Solutions avec les sociétés Ritme et Alfasoft AB offrent une nouvelle plateforme de renseignements de recherche SaaS aux chercheurs dans les domaines scientifiques, techniques et médicaux




Reprints Desk etabliert neuen Europäischen Vertriebskanal, bietet Forschern schnellen Zugang zu Inhalten und Daten

Tue, 18 Apr 2017 03:00:00 EDT

Die Tochtergesellschaft von Research Solutions vertreibt neue Software-as-a-Service (SaaS)-Research Plattform für Forscher und Wissenschaftler zusammen mit Vetriebspartnern Ritme Informatique SA und Alfasoft AB




Reprints Desk Partners With European Resellers, Provides One-Click Access To Content And Data For Researchers

Tue, 18 Apr 2017 03:00:00 EDT

Research Solutions Subsidiary's Reseller Agreements with Ritme Informatique SA and Alfasoft AB Deliver New SaaS Research Intelligence Platform to STM Researchers




CaliPharms Enters Acquisition Discussions with California Cannabis Retailers, Inc.

Mon, 17 Apr 2017 20:05:46 EDT

RIVERSIDE, CA--(Marketwired - Apr 17, 2017) - CaliPharms, Inc. (OTC PINK: KGET), a Company operating in the California Medicinal Cannabis industry, publicly trading under the OTC Markets symbol "KGET" is pleased to announce that CaliPharms has entered into acquisition discussions with United Cannabis Retailers, Inc. United Cannabis Retailers, Inc. is a cannabis product development company entering unfulfilled market niches in the cannabis sector. UCR is rolling out their first conceptual product line Canna-Kitchen this year. UCR is focused on promoting its brands.




CBIS Pushes Up the Seeding Schedule Next Month to 350 Acres Set to Include Additional 100 Acres in Minden Carson Valley Property Along with the San Joaquin Valley Property for its Industrial Commercial Hemp Grow Initiatives

Mon, 17 Apr 2017 14:15:20 EDT

Bringing Outdoor Cultivation Ready Land to 15.2 Million Square Feet in California and Nevada for its Industrial Commercial Hemp Grow Initiatives




NSAV Cannabis Division Announces Opening of New Office in Shanghai, China

Mon, 17 Apr 2017 10:00:02 EDT

CRESCO, PA--(Marketwired - Apr 17, 2017) - Net Savings Link, Inc. (OTC: NSAV) announced today that the company will be opening an office in Shanghai, China next month, with the primary goal to expand its medical cannabis technology business. The Company is presently in the final stages of deciding from several premier locations in the world's largest city. NSAV views the opening of its flagship China office as both a significant opportunity and a vital necessity, given that China is the world's largest producer of cannabis sativa seeds, accounting for nearly 40% of global production.




Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model

Mon, 17 Apr 2017 09:45:00 EDT

EAST SETAUKET, NY--(Marketwired - Apr 17, 2017) - Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) presented a late-breaking abstract entitled "Protein phosphatase 2A inhibition with a novel small molecule inhibitor, LB-100, achieves durable immune-mediated antitumor activity when combined with PD-1 blockade in a preclinical model" as a poster (abstract number LB-193) at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, DC on April 4th. This research was done in collaboration with scientists at the National Institute of Neurological Disorders and Stroke (NINDS), NIH.




Pressure BioSciences, Inc. Appoints Joseph L. Damasio Jr. as Vice President of Finance and Chief Financial Officer

Mon, 17 Apr 2017 09:12:55 EDT

SOUTH EASTON, MA--(Marketwired - Apr 17, 2017) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that Mr. Joseph L. Damasio Jr. joined the Company as its Vice President of Finance and Chief Financial Officer ("CFO") on April 10, 2017.




Biomerica Announces Third Quarter Financial Results, Sales up 13.9% for Nine Months

Mon, 17 Apr 2017 08:19:00 EDT

IRVINE, CA--(Marketwired - April 17, 2017) - Biomerica, Inc. (NASDAQ: BMRA) today reported net sales of $4,342,247 for the nine months ending February 28, 2017, compared to $3,813,683 for the period ended February 29, 2016. Sales for the three months ending February 28, 2017 were $1,499,930 compared to $1,361,608 for the period ended February 29, 2016.